Maxygen, Inc. http://www.alacrastore.com/company-snapshot/Maxygen_Inc-2100277 Tuesday, October 07, 2008 2:07:32 AM 2100277 Maxygen, Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/ccbn/T1905443ccbn/T1905443norm...Good day, ladies and gentlemen. I would now like to turn the presentation over for today's call Ms. Michele Boudreau. You may proceed.... 7/31/2008 9:06:00 PMMaxygen, Inc.54.0000FinalMaxygen, Inc. Q2 2008 Earnings Conference Call TranscriptMAXY4:30pm ETTranscriptT1905443Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-26833944newstex/BW-0001-26833944xml Jul. ##, #### (Business Wire) -- Maxygen, Inc. (Nasdaq:MAXY) will host a conference call to discuss the companya€™s second quarter #### financial results and business updates at #:## p.m. ET (#:## p.m. PT) on Thursday, July ##, ####....0400000004002000040020060401600004016048040160187/22/2008 10:19:33 AM180000001800400018008000Business WireBW-0001-26833944MAXYGEN INCRUSSELL J HOWARDMAXYNewsNewstexUS - Bayer Healthcare AG, a unit of Bayer AG, agreed to acquire the Haemophilia programme assets of Maxygen Inc, a biotechnology company, for $### mil. The consideration was to consist of $## mil and up to $## mil in profit-related payments.7/3/2008 11:02:13 AM07287J57822W072730577776Bayer Healthcare AGMaxygen Inc-Haemophilia Programme AssetsBayer AGMaxygen Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/Bayer_Healthcare_AG_acquires_Maxygen_Inc_Haemophilia_from_Maxygen_Inc-1992780020sdc/19927800201992780020Copyright © 2008, Thomson Financial, All Rights ReservedDrugsGermanyPharmaceutical preparations2834FFForeignSubsidiary2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances2821:Plastics materials and synthetic resins2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec2899:Chemicals and chemical preparations, necDrugsUnited StatesBiological products, except diagnostic substances2836CACaliforniaSubsidiary883873001Mnfr,whl pharmaceuticalsBiotech coCashEarnoutAssets1026702001Jul 3 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.00000Bayer HealthCare AG, locatedin Leverkusen, Germany,manufactures pharmaceuticalproducts focused on productsthat diagnose, prevent, andtreat disease of both humansand animals worldwide. Theyhave four divisions: AnimalHealth (veterinary drugs);Consumer Care (OTC meds);Diabetes Care; andPharmaceuticals (representedby Bayer-Schering Pharma andBayer HealthcarePharmaceuticals), operating inmore than 120 countriesworldwide. The company wasfounded in 1863.Bayer HealthCare AG, located in Leverkusen, Germany,manufactures pharmaceutical products focused on productsthat diagnose, prevent, and treat disease of both humans andanimals worldwide. They have four divisions: Animal Health(veterinary drugs); Consumer Care (OTC meds); Diabetes Care;and Pharmaceuticals (represented by Bayer-Schering Pharmaand Bayer Healthcare Pharmaceuticals), operating in morethan 120 countries worldwide. The company was founded in1863.Bayer HealthCare AG, located in Leverkusen, Germany, manufactures pharmaceutical products focused on products that diagnose, prevent, and treat disease of both humans and animals worldwide. They have four divisions: Animal Health (veterinary drugs); Consumer Care (OTC meds); Diabetes Care; and Pharmaceuticals (represented by Bayer-Schering Pharma and Bayer Healthcare Pharmaceuticals), operating in more than 120 countries worldwide. The company was founded in 1863.1.000002.000003.000004.000005.00000The Haemophilia programmeassets of Maxygen Inc, locatedin California, which treatsblood-clotting disorderhaemophilia.The Haemophilia programme assets of Maxygen Inc, located inCalifornia, which treats blood-clotting disorderhaemophilia.The Haemophilia programme assets of Maxygen Inc, located in California, which treats blood-clotting disorder haemophilia.0.000000.000000.000000.00000YU.S. Dollar02 Jul 08Wed, 02 Jul 2008 00:00:00 ESTDate Announced: 07/02/2008Date Effective:Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.00000120 U.S. Dollar120.000000.00000120 U.S. Dollar120.000000.000000.000000.000000.00000120.00000120 U.S. Dollar1.00000N60.214000.000000.000000.000000.000000.00000120.00000120.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.00000US - Bayer Healthcare AG, aunit of Bayer AG, agreed toacquire the Haemophiliaprogramme assets of MaxygenInc, a biotechnology company,for $120 mil. Theconsideration was to consistof $90 mil and up to $30 milin profit-related payments.US - Bayer Healthcare AG, a unit of Bayer AG, agreed to acquire the Haemophilia programme assets of Maxygen Inc, a biotechnology company, for $120 mil. The consideration was to consist of $90 mil and up to $30 mil in profit-related payments.US - Bayer Healthcare AG, a unit of Bayer AG, agreed to acquire the Haemophilia programmeassets of Maxygen Inc, a biotechnology company, for $120 mil. The consideration was toconsist of $90 mil and up to $30 mil in profit-related payments.US - Bayer Healthcare AG, a unit of Bayer AG, agreed to acquire the Haemophilia programme assets of Maxygen Inc, a biotechnology company, for $120 mil. The consideration was to consist of $90 mil andup to $30 mil in profit-related payments.US - Bayer Healthcare AG, a unit of Bayer AG, agreed to acquire the Haemophilia programme assets of Maxygen Inc, a biotechnology company,for $120 mil. The consideration was to consist of $90 mil and up to $30 mil in profit-related payments.Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations100861001FrankfurtGermany2833ForeignPublicBAY2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations617238002NasdaqUnited States2836CaliforniaPublicMAXY120.00000120.00000120.0000060.21400Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/ccbn/T1889029ccbn/T1889029norm...Good day, ladies and gentlemen, and welcome to the Maxygen conference call. My name is Carmen, and I will be your coordinator for today. (OPERATOR INSTRUCTIONS). As a reminder, ladies and gentlemen, this conference is being recorded for replay purposes. I would now like to turn the presentation over to your host for today's call, Ms. Michele Boudreau, Director of Investor and Public Relations. Please proceed. ... 7/2/2008 1:04:00 PMMaxygen, Inc.54.0000FinalMaxygen, Inc. Conference Call TranscriptMAXY8:30am PTTranscriptT1889029Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1830428ccbn/T1830428norm...Good day, ladies and gentlemen and welcome to the first quarter #### Maxygen Inc. earnings conference call. I will be your coordinator for today. At this time, all participants are in listen-only mode. We'll facilitate a question-and-answer session towards the end of this conference. (OPERATOR INSTRUCTIONS) I would like to turn the presentation over to your host for today's call, Director of Investor and Public Relations, Ms. Michele Boudreau. ... 5/6/2008 12:06:00 PMMaxygen, Inc.54.0000FinalQ1 2008 Maxygen, Inc. Earnings Conference Call TranscriptMAXY11:30am ETTranscriptT1830428Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1764209ccbn/T1764209norm... - Maxygen, Inc. - CEOGood morning and welcome to the Maxygen presentation. I will be making some forward looking statements and you can refer to our published accounts of the risks involved in investment in Maxygen. Maxygen is dedicated to making Biosuperior forms of protein drugs. That is we look at multibillion dollar protein drugs already on the market, figure out what their deficiencies are, either a problem to be removed or an advantage to be enhanced. And then we use our proprietary technologies, together with non-proprietary technologies, to make what we call a Biosuperior protein pharmaceutical. That is using our MolecularBreeding Technology Platform. We have leveraged that platform over the years. Interestingly we have not financed since #### in our Company because we have been able to leverage the technology to sell and spinoff other companies from which we have received liquidity. At this time we still own ##% ownership in a private company dedicated to advanced pharmaceuticals... 2/19/2008 3:06:00 PMMaxygen, Inc.54.0000FinalMaxygen, Inc. at Roth Capital Partners 20th Annual OC Growth Stock Conference TranscriptMAXY9:00am PTTranscriptT1764209Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1751072ccbn/T1751072normQ# #### Maxygen, Inc. Earnings Conference Call2/12/2008 5:06:00 PMMaxygen, Inc.54.0000FinalQ4 2007 Maxygen, Inc. Earnings Conference Call TranscriptMAXY11:30am ETTranscriptT1751072Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1730605ccbn/T1730605norm1/7/2008 3:22:00 PMMaxygen, Inc.54.0000FinalMaxygen, Inc. at JPMorgan Healthcare Conference TranscriptMAXY9:00am PT... - JPMorgan - AnalystGood morning and welcome to the JP Morgan Healthcare Conference. My name is Silke Kueck. I'm part of [the] Biochemical and Life Sciences research team at JPMorgan. Today it is my pleasure to introduce Maxygen. Maxygen is a company that uses its gene [shuffling] technologies to develop improved versions of protein pharmaceuticals. The Company's current pipeline includes product candidates in the area of chemotherapy-induced [neutrophilia], also hemophilia and also rheumatoid arthritis. We are interested to learn more about these projects today. Representing for Maxygen this morning is Russell Howard, Maxygen's CEO, and Maxygen's Chief Medical Officer, Mr. Santosh Vettucadden.... TranscriptT1730605Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1673191ccbn/T1673191norm11/1/2007 1:06:00 PMMaxygen, Inc.54.0000FinalQ3 2007 Maxygen, Inc. Earnings Conference Call TranscriptMAXY11:30am ET...Good day, ladies and gentlemen. And welcome to the third quarter #### Maxygen Incorporated earnings conference call. My name is Shawn and I'll be your operator for today. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session toward the end of this conference. (OPERATOR INSTRUCTIONS) I would now like to turn the presentation over to your host for today's call, Ms. Michele Boudreau, Director of Investor Relations. Please proceed. ... TranscriptT1673191Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/srp/233396124srp/233396124norm...Address:### Galveston Drive, Redwood City, California ##### Incorporated:DelawareWeb Site: www.maxygen.comSIC Classification: Commercial Physical and Biological Research (####) Business Description: Maxygen, Inc. is a biotechnology company focused on using its protein optimization and modification technologies to create and develop novel therapeutic and industrial products. The company is a leader in the field of directed molecular evolution, a process by which genes are modified for specific commercial uses. The company's technologies bring together advances in molecular biology and protein modification to help create novel biotechnology products. Indices:Russell ####, Russell #### IPO Date: ##-##-####... 233396124577776107MAXY10/6/2006 12:23:00 PM233396124Credit & Investment ResearchSharkRepellent.net